Mylan Reports Second Quarter 2017 Results and Updates 2017 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Mylan (MYL) PT Lowered to $32 at RBC Capital; Reiterates Sector Perform
August 9, 2017 4:56 PM EDTRBC Capital lowered its price target on Mylan (NASDAQ: MYL) to $32.00 (from $33.00) while maintaining a Sector Perform rating following the company's 2Q.
The company cut its $6.00 2018E EPS target to now >$5.40 which still implies >20% EPS growth. RBC's new 2017-19E EBITDA forecasts are $3.72 billion, $3.86 billion and $3.91 billion.
... MoreMylan (MYL) PT Lowered to $30 at Cowen Following 2Q Results
August 9, 2017 4:48 PM EDTCowen lowered its price target on Mylan (NASDAQ: MYL) to $30.00 (from $43.00) while maintaining a Market Perform rating following the company's 2Q results. Results were underwhelming and fell short of the Street as the North American business continues to experience headwinds due to... More
Evecore ISI's Raffat sees ~$29/sh valuation floor on Mylan (MYL) on the new guidance
August 9, 2017 9:32 AM EDTEvecore ISI's Umer Raffat said he gets to a ~$29/sh valuation floor on Mylan (NASDAQ: MYL) on the new guidance
Mylan (MYL) Misses Q2 EPS by 6c, Guides FY17 EPS Below Views
August 9, 2017 8:04 AM EDTMylan (NASDAQ: MYL) reported Q2 EPS of $1.10, $0.06 worse than the analyst estimate of $1.16. Revenue for the quarter came in at $2.96 billion versus the consensus estimate of $3.04 billion.
GUIDANCE:
Mylan sees FY2017 EPS of $4.30-$4.70 vs consensus of $5.12 on revenue of $11.5 to $12.5 billion vs consensus of $12.46 billion.
FY18 target EPS moved to $5.40 from $6 vs consensus of $5.64.
Mylan CEO Heather Bresch commented, "Our industry, along with the entire healthcare sector, is at an inflection point. This is providing investors an opportunity to differentiate between pharmaceutical companies focused... More
